Immunome, Inc. (IMNM) Stock: News, Analysis, Q&A, and Insights

Investment Analysis Report: IMNM

Overview

In this investment analysis report, we will delve into a comprehensive evaluation of IMNM, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash fl...

Technical Analysis of IMNM 2024-05-03

Overview:

In analyzing the technical indicators for IMNM over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...

Recent News & Updates

2024-05-02 08:00
Immunome Appoints Kinney Horn as Chief Business Officer(Business Wire)
2024-05-01 20:00
Immunome Appoints Kinney Horn as Chief Business Officer(Businesswire)
2024-04-30 07:29
--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target(MT Newswires)
2024-04-26 10:00
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for(Zacks)
2024-04-25 22:00
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for(Zacks)
2024-04-25 08:26
Immunome Appoints Sandra M. Swain to Board of Directors(Business Wire)
2024-04-24 20:26
Immunome Appoints Sandra M. Swain to Board of Directors(Businesswire)
2024-04-05 08:00
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting(Business Wire)
2024-04-04 20:00
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting(Businesswire)
2024-04-04 05:56
New Strong Sell Stocks for April 4th(Zacks)
2024-03-28 16:02
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets(Business Wire)
2024-03-28 11:53
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023(Investorplace)
2024-03-28 04:02
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets(Businesswire)
2024-03-26 08:00
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala(Business Wire)
2024-03-26 08:00
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome(GlobeNewswire)
2024-03-25 20:00
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala(Businesswire)
2024-03-25 20:00
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome(Globenewswire)
2024-03-22 06:48
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions(Simply Wall St.)
2024-03-17 17:44
Arrayjets ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies(Businesswire)
2024-03-07 08:00
Immunome to Participate in the Leerink Partners Global Biopharma Conference(Business Wire)
2024-03-06 19:00
Immunome to Participate in the Leerink Partners Global Biopharma Conference(Businesswire)
2024-03-03 18:00
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors(Globenewswire)
2024-03-01 08:00
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference(Business Wire)
2024-02-29 19:00
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference(Businesswire)
2024-02-20 08:15
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors(Business Wire)
2024-02-20 08:00
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors(GlobeNewswire)
2024-02-19 19:15
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors(Businesswire)
2024-02-19 19:00
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors(Globenewswire)
2024-02-16 16:05
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares(Business Wire)
2024-02-16 03:05
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares(Businesswire)

Page 1 of 6

previousnext

Home

Market Lens

Ideas Explorer

History

Recent Activity

IMNM

Performance

Profile

Investment Analysis Report: IMNM

Overview

Technical Analysis of IMNM 2024-05-03

Overview:

Recent News & Updates